Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study

Julio I. Osende2, Marta Ruiz-Ortega1, Luis Miguel Blanco-Colio1 and Jesus Egido1

1Renal and Vascular Research Laboratory, Fundación ‘Jiménez-Díaz’ (Autonoma University) and 2Cardiology Service, ‘Gregorio Marañón’ General University Hospital, Madrid, Spain

Correspondence and offprint requests to: Professor Jesús Egido, Renal and Vascular Research Laboratory, Fundación Jimenez-Diaz. Avda Reyes Católicos, 2, 28040 Madrid, Spain. Email: jegido{at}fjd.es

Keywords: hypertension; primary prevention; statins



   Introduction
 Top
 Introduction
 Comparison of the ASCOT-LLA...
 Mechanisms involved in the...
 Unresolved issues in the...
 References
 
The recently published Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Study Trial (ASCOT-LLA) [1] provides interesting evidence for the use of statins in hypertensive patients with average cholesterol levels and other cardiovascular risk factors. In this study, 19 342 hypertensive patients with at least three other cardiovascular risk factors were randomized to two antihypertensive regimes (amlodipine and/or perindopril vs atenolol and/or clorthalidone) and were planned to be followed for 5 years.

The LLA was comprised of those patients with baseline total cholesterol levels <=6.5 mmol/l (~260 mg/dl), who were also randomized to receive daily atorvastatin 10 mg vs placebo. A total of 10 305 patients entered in the LLA, which was stopped prematurely by the safety committee after a mean follow-up of only 3.3 years due to a significantly lower incidence of the primary objective (non-fatal acute myocardial infarction and fatal coronary artery disease) in the atorvastatin group. The results showed that 100 patients in the atorvastatin arm and 154 in the placebo arm met criteria for the primary end-point (relative risk reduction 36%, P = 0.0005). The analysis also demonstrated that the clinical benefit started after only a year of treatment, similarly to secondary prevention randomized studies with statins. The study also showed a significant reduction in both fatal and non-fatal stroke in the atorvastatin group (relative risk reduction of 27%) [1]. Average serum cholesterol levels in the atorvastatin group decreased by 1.3 and 1.1 mmol/l after 1 and 3 years, respectively, with a total follow-up of 3 years compared with the placebo group.



   Comparison of the ASCOT-LLA trial with other major clinical statin trials
 Top
 Introduction
 Comparison of the ASCOT-LLA...
 Mechanisms involved in the...
 Unresolved issues in the...
 References
 
These data confirm and expand the benefit of statin treatment in patients at high risk of developing cardiovascular events. A high-risk patient profile was initially considered to be represented by those with previous myocardial infarction [2], a patient population known to have a higher incidence of events than the general population. The benefit of statin treatment was later expanded to those without a history of myocardial infarction and either moderate hypercholesterolaemia [3] or low levels of high-density lipoprotein-cholesterol [4]. The emerging new concept that the ASCOT-LLA study addresses is the clinical management of hypertensive patients without overt hypercholesterolaemia but with at least three other cardiovascular risk factors, a common finding in clinical practice. In this regard, both the ASCOT-LLA and the recently published Heart Protection Study (HPS) [5] show clear benefit of statin treatment in patients at high risk of developing cardiovascular events, even those with normal baseline cholesterol levels in primary prevention. However, differences between the two studies need to be pointed out. The ASCOT-LLA targeted hypertensive patients meeting criteria for high risk due to the concurrence of many risk factors, a well-known prognostic marker. The presence of prior atherosclerotic disease or diabetes (as a surrogate) was not required. The use of a low dose of atorvastatin showed clinical benefit after a mean follow up of 3.3 years. The HPS study patients had previous atherosclerotic vascular disease or diabetes (known to have a similar risk profile). In them, a relatively high statin dose was associated with clinical benefit after a 5-year follow-up, since this study was not finished prematurely. Patients in the ASCOT-LLA study were apparently at lower risk than those in the HPS study. Also, the ASCOT-LLA study design selected a relative low dose of statin compared with the HPS, so a low incidence of adverse effects would be anticipated, making it an attractive long-term preventive therapy for a wide range of physicians. The results of the ASCOT-LLA trial proved to be independent of the degree of blood pressure reduction associated with intense lipid lowering [6], as both the atorvastatin and the placebo group showed a similarly good blood pressure control.



   Mechanisms involved in the benefit of statin treatment in hypertensive patients
 Top
 Introduction
 Comparison of the ASCOT-LLA...
 Mechanisms involved in the...
 Unresolved issues in the...
 References
 
The clinical benefit of atorvastatin in this patient population is probably explained by both lipid-dependent and lipid-independent effects of atorvastatin. These so-called pleiotropic effects of statins [7] may contribute to alter the progression of atherosclerosis, independently of cholesterol lowering. Statins are known to improve endothelial function [8], reduce blood thrombogenicity [9] and exert anti-inflammatory actions [10]. These non-lipid-related actions could be due to the inhibition of isoprenoid intermediates of the cholesterol biosynthetic pathway, such as farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) [7]. FPP and GGPP mediate the post-translational modification (prenylation) of many proteins, including the small G proteins (Ras, Rac, Rab and Rho), which are involved in cell growth regulation/apoptosis, actin cytoskeleton organization, membrane trafficking and gene expression [7]. The statin-induced inhibition of the prenylation of these proteins impairs their submembranous localization, limiting their activation and full functionality. In vascular smooth muscle cells, we and others have shown that statins regulate the cellular localization and activation of Ras and Rho proteins [11].

Table 1 summarizes the potential benefit of statin treatment in hypertensive patients. The statin-induced inhibition of Rho and its downstream target Rho-kinase function may have beneficial effects in hypertensive patients. Angiotensin-II (AngII), acting through AT1 receptors, plays a key role in the progression of vascular damage associated with hypertension. AngII regulates cell growth, hypertrophy, the production of extracellular matrix proteins and pro-inflammatory mediators [12]. AT1 receptors are coupled to G proteins and require functional small G proteins, including RhoA, Ras, Rac1 and the Rho/kinase system [12], to exert responses such as actin reorganization, vasoconstriction, hypertrophy, and monocyte chemoattractant protein 1 (MCP-1) and connective tissue growth factor (CTGF) expression. Experimental studies have established that statins regulate several AngII responses. In cultured vascular smooth muscle cells and monocytes, we have observed that atorvastatin decreased the activation of transcription factors AP-1 and NF-{kappa}B and inhibited the induction of pro-inflammatory genes [MCP-1 and interleukin-8 (IL-8)] caused by AngII [13]. These effects were reversed by intermediary compounds of the cholesterol pathway, such as mevalonate and the isoprenoids FPP and GGPP. We recently observed that in vascular smooth muscle cells, statins decreased AngII-induced CTGF production, mediated by inhibition of isoprenoids [14]. Statins also show antioxidant properties and restore nitric oxide bioactivity [15]. The AT1 receptor regulates reactive oxygen species (ROS) production through stimulation of NAD(P)H oxidase. Statins decrease the level of AT1 receptors [16], the expression of NAD(P)H oxidase subunits [17] and AngII-induced ROS production [18]. On the other hand, hypercholesterolaemia is associated with elevated AT1 receptor levels, suggesting a major biological response to AngII [16]. All these observations point to a direct interaction between statins and AngII-elicited intracellular signals that could have important clinical consequences.


View this table:
[in this window]
[in a new window]
 
Table 1. Potential cholesterol-independent mechanisms implicated in the clinical benefit of statin treatment in hypertensive patients

 


   Unresolved issues in the ASCOT-LLA trial
 Top
 Introduction
 Comparison of the ASCOT-LLA...
 Mechanisms involved in the...
 Unresolved issues in the...
 References
 
The safety committee board prematurely discontinued the ASCOT-LLA trial, considering that stopping rules for the primary end-point were significantly exceeded, although no significant reduction in total mortality was shown. This fact also left some unresolved issues open to discussion [19]. For instance, although women on atorvastatin treatment had 20% fewer events, this difference did not reach significance probably due to the limited power of the analysis (there were only 36 primary end-points among women) at the time the trial was stopped. A comparable pattern was described in diabetic patients, in whom no clear benefit of atorvastatin treatment was found despite a 23% reduction in cardiovascular events and procedures in the atorvastatin group. Similarly, other important subgroups such as patients with left ventricular hypertrophy, those <=60 years old, patients without renal dysfunction and patients with the metabolic syndrome showed no benefit with atorvastatin. The low statistical power of some of the available data for pre-specified subgroups is therefore amenable to interpretation. However, as Trewby et al. [20] pointed out, the absolute risk reduction for preventive treatments such as stains, ß-blockers, some antihypertensive treatments, angiotensin-converting enzyme inhibitors and antiplatelet drugs is < 1% per year even in high risk patients, and of the same order of magnitude as atorvastatin in the ASCOT-LLA trial. Therefore, the possibility of improving the prognosis of hypertensive patients has to be welcome, despite the need for further research to show better treatment options for our patients.



   Acknowledgments
 
Supported by grants 01/3130 (PI020822), 02/3093 and PI02/1047 from the "Fondo de Investigacion Sanitaria", Spain, grant 08.4/0021.1/2003 from the "Comunidad Autonoma de Madrid", Spain and a grant from the "Spanish Network on Cardiovascular Disease".

Conflict of interest statement. None declared.



   References
 Top
 Introduction
 Comparison of the ASCOT-LLA...
 Mechanisms involved in the...
 Unresolved issues in the...
 References
 

  1. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–1158[CrossRef][ISI][Medline]
  2. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383–1389[ISI][Medline]
  3. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307[Abstract/Free Full Text]
  4. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279: 1615–1622[Abstract/Free Full Text]
  5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22[CrossRef][ISI][Medline]
  6. Ferrier KE, Muhlmann MH, Baguet JP et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020–1025[CrossRef][ISI][Medline]
  7. Takemoto M, Liao J. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Arterioscler Thromb Vasc Biol 2001; 21: 1712–1719[Abstract/Free Full Text]
  8. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–1131[Abstract/Free Full Text]
  9. Rauch U, Osende JI, Chesebro J et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000; 153: 181–189[CrossRef][ISI][Medline]
  10. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003; 63: 12–23[CrossRef][ISI][Medline]
  11. Blanco-Colio LM, Villa A, Ortego M et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin induce apoptosis in vascular smooth muscle cells by downregulation of Bcl-2 expression and RhoA prenylation. Atherosclerosis 2002; 161: 17–26[CrossRef][ISI][Medline]
  12. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003: 5: 73–79[ISI][Medline]
  13. Ortego M, Bustos B, Hernández-Presa Ma et al. Atorvastatin reduces NF-{kappa}B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253–261[CrossRef][ISI][Medline]
  14. Ruperez M, Blanco-Colio L, Lorenzo O, Esteban V, Egido J, Ruiz-Ortega M. HMG-CoA reductase inhibitors regulate angiotensin II responses via Rho proteins: modulation of connective tissue growth factor in vascular smooth muscle cells. Circulation 2002; 106 [Suppl I]
  15. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction—modulation by statins. Endothelium 2003; 10: 23–33[CrossRef][Medline]
  16. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131–2134[Abstract/Free Full Text]
  17. Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300–305[Abstract/Free Full Text]
  18. Wassmann S, Laufs U, Baumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450–1457[Abstract/Free Full Text]
  19. ASCOT-LLA. Questions about the benefits of atorvastatin. Lancet 2003; 361: 1985–1987
  20. Trewby P, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs preventive enough? A study of patient's expectation of benefit from preventive drugs. Clin Med 2002; 2: 527–533[ISI][Medline]




This Article
Extract
FREE Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Search for citing articles in:
ISI Web of Science (2)
Disclaimer
Request Permissions
Google Scholar
Articles by Osende, J. I.
Articles by Egido, J.
PubMed
PubMed Citation
Articles by Osende, J. I.
Articles by Egido, J.